Related coverage linked through entity extraction aliases.
May 21, 2026
A systematic review and meta-analysis found high infection rates with teclistamab in relapsed/refractory multiple myeloma. Five studies showed pooled infection rates of 56.5% for any grade and 27.6% for grade 3 or higher.
May 18, 2026
The FDA pulled back publication of several studies on COVID-19 and shingles vaccines. The blocked studies involved millions of patient records, and two COVID-19 papers were withdrawn in October 2025.
May 16, 2026
FDA approves Genentech's Tecentriq as first ctDNA-guided adjuvant therapy for muscle-invasive bladder cancer, and Venclexta plus acalabrutinib as first all-oral fixed-duration regimen for CLL.
May 13, 2026
The FDA reversed its refusal to review Moderna’s mRNA flu vaccine application and accepted a revised filing with split age cohorts and a post-market study for adults over 65. The reversal came amid broader vaccine regulatory uncertainty and industry concern about unpredictable review timelines.
May 12, 2026
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
May 02, 2026
A federal judge froze appointments to the CDC’s ACIP, halted its votes, and paused recent HHS vaccine policy changes. The ruling leaves several FDA-approved vaccines pending review.
May 01, 2026
India has eased Press Note 3 FDI rules with a beneficial ownership test, 10% safe harbour for non-controlling LBC investments, and 60-day fast-track approvals in seven manufacturing sectors. The revised norms aim to clear 600 pending applications and boost gross FDI to $90 billion in FY26.
Apr 29, 2026
GeoVax is advancing Gedeptin toward a Phase 2 trial in head and neck cancer and has secured an exclusive license from Emory University for Gedeptin-ICI combination technology. The therapy has Orphan Drug Designation for oral and pharyngeal cancers.
Apr 27, 2026
The Lancet refused a U.S. Senate request for evidence on COVID-19 origins. Purdue Pharma's sentencing was delayed, while insurers moved to reduce prior-authorization paperwork.
Apr 25, 2026
BioNTech enters May with first-quarter earnings due May 5 and a May 15 shareholder vote on a capital increase. The company is pushing its oncology pipeline as COVID-19 vaccine sales decline.
Apr 24, 2026
The EMA’s CHMP recommended approval of Sanofi’s Cenrifki (tolebrutinib) for non-relapsing secondary progressive multiple sclerosis. The phase 3 HERCULES study showed reduced disability progression, while liver injury remains an identified safety risk.
Apr 23, 2026
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Apr 23, 2026
The acting director of the CDC delayed publication of a report showing the COVID-19 vaccine cut emergency department visits and hospitalizations for healthy adults last winter by about half. The Department of Health and Human Services did not immediately respond to request for comment.
Apr 22, 2026
The mRNA synthesis and manufacturing market is projected to grow from USD 2.23 billion in 2024 to USD 2.96 billion by 2029 at a 5.8% CAGR. Consumables led in 2023, while Asia Pacific is expected to be the fastest-growing region.
Apr 22, 2026
Deutsche Bank upgraded Merck to Buy and raised its price target to $150 from $115, citing a clear path beyond Keytruda’s patent expiration. Merck meanwhile forecast 2026 revenue of $65.5 billion to $67.0 billion and said it faces a $2.5 billion headwind this year.
Apr 18, 2026
The FDA approved acalabrutinib plus venetoclax for previously untreated CLL/SLL based on phase 3 AMPLIFY data. The fixed 14-month regimen improved progression-free survival versus chemotherapy.
Apr 16, 2026
A study in The Lancet Child & Adolescent Health linked academic pressure at age 15 to higher depressive symptoms through age 22 and self-harm risk through age 24.
Apr 12, 2026
Invivyd reported progress in the Phase 3 DECLARATION trial of VYD2311, with top-line data now expected in Q3 2026 after a sample size increase of about 500 subjects. The company also aligned with the FDA on the LIBERTY Phase 3 study, a pediatric study plan for DRUMMER, and advanced measles antibody candidate VMS063.
Apr 07, 2026
Tennessee has implemented comprehensive pharmacist scope-of-practice expansion allowing independent prescribing, testing, and treatment for select conditions. The legislation enables pharmacists to prescribe medications including antivirals, contraceptives, and naloxone without collaborative agreements. This expansion aims to improve healthcare access, particularly in rural areas with provider shortages.
Apr 02, 2026
A 16-year study links higher vitamin D levels in middle age to lower tau protein deposits in the brain, while a major COVID-19 trial finds vitamin D doesn't reduce acute severity but may help with long COVID recovery. Separate research shows supplementation improves vitamin D levels and stabilizes immune profiles in athletes and non-athletes.
